Human histocompatibility leukocyte antigen (HLA)-DM is a facilitator of antigen presentation via major histocompatibility complex (MHC) class II molecules. In the absence of HLA-DM, MHC class II molecules do not present natural peptides, but tend to remain associated with class II-associated invariant chain peptides (CLIP). Recently, DM was shown to catalyze the release of CLIP from HLA-DR. We have investigated which peptides bound to HLA-DR are vulnerable to release upon encountering DM. By directed substitution of allele-specific anchor residues between CLIP and DR3-cognate peptides and the application of recombinant DM we show that DM catalyzes the release of those peptides bound to HLA-DR3 that do not have appropriate anchor residues and, hence, no optimal ligand binding motif. Thus, HLA-DM acts as a peptide editor, facilitating selection of peptides that stably bind to class II molecules for eventual presentation to the immune system from the pool of available peptides.
Skip Nav Destination
Article navigation
1 November 1996
Article|
November 01 1996
Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.
S M van Ham,
S M van Ham
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
Search for other works by this author on:
U Grüneberg,
U Grüneberg
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
Search for other works by this author on:
G Malcherek,
G Malcherek
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
Search for other works by this author on:
I Bröker,
I Bröker
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
Search for other works by this author on:
A Melms,
A Melms
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
Search for other works by this author on:
J Trowsdale
J Trowsdale
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
Search for other works by this author on:
S M van Ham
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
U Grüneberg
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
G Malcherek
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
I Bröker
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
A Melms
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
J Trowsdale
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
Online ISSN: 1540-9538
Print ISSN: 0022-1007
J Exp Med (1996) 184 (5): 2019–2024.
Citation
S M van Ham, U Grüneberg, G Malcherek, I Bröker, A Melms, J Trowsdale; Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.. J Exp Med 1 November 1996; 184 (5): 2019–2024. doi: https://doi.org/10.1084/jem.184.5.2019
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement